INVESTOR PRESENTATION 2019 Better Data, Better Health WHO ARE WE? - PowerPoint PPT Presentation

TSX-V: AVCR ! OTCQB: AVCRF INVESTOR PRESENTATION 2019 Better Data, Better Health

WHO ARE WE? Avricore is a total health innovator capitalizing on technological advancements and consumer health trends, offering consumers, health providers and life- science companies the ability to take control of both spending and health outcomes. We intend on become the world’s largest health data company and are utilizing point-of-care technologies within community pharmacy to achieve this. www.avricorehealth.com

QUICK OVERVIEW ! Converted from VANC Pharmaceuticals, a generic drug maker with 91 generic offerings in 2018 to become Avricore Health Inc. ! Avricore is currently selling Hema-fer, an OTC iron supplement, to pharmacies across Canada. ! In the transition, Avricore purchased two technologies, the Avricore Platform (formerly Corozon Platform) and HealthTab. ! The Company’s primary focus today is on developing a network of point-of-care analyzers that utilizes its HealthTab software in community pharmacy.

W E L C O M E T O H E A LT H TA B A N D T H E R A S T R M O D E L The patient driven R apid A ccess, S afety T est R eporting system ( RASTR )

Turnkey System 2 panels , 21 results Lab-accurate analyzer Secure online results In-store kiosk

• Proven point-of-care screening system, designed to support pharmacists evolving role. • Empowers patients to be proactive about their health by directly measuring and monitoring key safety tests and biomarkers of chronic disease. • Simple, fast, lab-accurate, and requires just a few drops of blood from a finger stick. • Results can be printed in-store or accessed securely online. • Watch short video here and visit our HealthTab website . •

R A S T R M O D E L • A network of HealthTab systems utilizing the Piccolo Analyzer in community pharmacies. • Running panels on consumers utilizing finger stick sample, monitoring up to 21 key bio-markers, and/or customizable tests. • Allows for API integration for better data flow and customization. • Provides harmonized, real-time data on consumer health. 1. The client purchases the drug or other health product. 2. The pharmacy leases the analyzers at a reasonable cost to become a part of the network. 3. The drug maker pays to access the network and sponsors test fees for consumer.

! OUR TEAM Dr. Robert Sindelar - Director Bob Rai - CEO & director David Farnfield – Director BOARD DIRECTORS David Hall - Chairman & Director Alan Arnstein ! - Director Mark Zhou – Board Advisor Ray Chepsiuk – Board Advisor Sherif Guorgui - Board Advisor BOARD ADVISORS Philippe Ungat – Board Advisor David Huston - Board Advisor Kiki Smith - CFO/Corporate Secretary Hector Bremner – EVP , Strategic Communications/Public Affairs MANAGEMENT ! Rodger Seccombe - Head of HealthTab Division FOR MORE INFORMATION ON OUR TEAM, PLEASE VISIT OUR WEBSITE

PROJECTIONS ())*+,-.+,/0 !"###$%&'( !)($%%% !)'$%%% !)&$%%% !)#$%%% !)%$%%% !($%%% !'$%%% !&$%%% !#$%%% !" !"#$ !"!" !"!# !"!! !"!% !"!& !"!' ())*+,-.+/012,34 !"###$%&'( !+#$%%% !+%$%%% !*$%%% !)$%%% !($%%% !#$%%% !' !"#$ !"!" !"!# !"!! !"!% !"!& !"!' !"#$%%%&

CAP STRUCTURE As of September, 2019 Includes shares issued to date as per the Lampyon agreement, the Healthtab Agreement, and the Corozon Agreement (please note: 681,818 of the Corozon shares are subject to a year hold, expiring on May 18, 2019). ** Does not include remaining shares to be issued pursuant to the Lampyon agreement, as these shares are based on calculating the volume weighed average closing share price on the last 5 trading days preceding the date of issue Common Shares Issued & Outstanding (per Computershare Report - January 7, 2019) ! 52,472,699 * Please see note above **Please see note above Reserved for Stock Options 3,181, 072 Reserved for Warrants @ $0.20 - Expiry Jun 26, 2022 1,791,159 Reserved for Finders Warrants @ $0.20 - Expiry Jun 26, 2022 - All warrants have been - exercised. Reserved for Warrants @ $0.20 - Expiry Aug 3, 2022 742,667 Reserved for Warrants @ $0.20 - Expiry Nov 27, 2022 2,872,000 Reserved for Emerald Warrants @ $0.33 (Supply & Distribution Agreement) - Expiry April 3,030,303 15, 2020 Reserved for Warrants @ $0.33 - Expiry Jul 31, 2020 5,416,135 Reserved for Warrants @ $0.15 - Expiry Aug 14, 2021 6,852,400 TOTAL 76,358,435

OUR PARTNERS

JOIN US IN REALIZING THIS OPPORTUNITY Avricore Health is seeking to secure 40 Piccolo Xpress analyzers and expand the RASTR network in the immediate future. The company has no competition in this field, yet. However, as we have demonstrated here, the POCT market is rapidly growing as established health data methods get “smart.” To learn more about how you can invest in the growth of this technology, or partner with us to test your consumers, please contact us at: investor@avricorehealth.com